Full text biomedical articles
A new paradigm for antiangiogenic therapy through controlled release of bevacizumab from PLGA nanoparticlesFlávia Sousa, Andrea Cruz, Pedro Fonte, Inês Mendes Pinto, Maria Teresa Neves-Petersen, Bruno Sarmento
Sci Rep. 2017; 7: 3736. Published online 2017 Jun 16. doi:Â 10.1038/s41598-017-03959-4
Bevacizumab, temozolomide, and radiotherapy for newly diagnosed glioblastoma: comprehensive safety results during and after first-line therapyFrank Saran, Olivier L. Chinot, Roger Henriksson, Warren Mason, Wolfgang Wick, Timothy Cloughesy, Sunita Dhar, Emanuela Pozzi, Josep Garcia, Ryo Nishikawa
Neuro Oncol. 2016 Jul; 18(7): 991â1001. Published online 2016 Jan 24. doi:Â 10.1093/neuonc/nov300
Population pharmacokinetic modeling of PF-06439535 (a bevacizumab biosimilar) and reference bevacizumab (Avastin®) in patients with advanced non-squamous non-small cell lung cancerCheryl S. W. Li, Kevin Sweeney, Carol Cronenberger
Cancer Chemother Pharmacol. 2020; 85(3): 487â499. Published online 2019 Nov 26. doi:Â 10.1007/s00280-019-03946-8
Quantification of Bevacizumab Activity Following Treatment of Patients With Ovarian Cancer or GlioblastomaChristophe Lallemand, Rosa Ferrando-Miguel, Michael Auer, Sarah Iglseder, Theresa Czech, Anouk Gaber-Wagener, Franziska Di Pauli, Florian Deisenhammer, Michael G. Tovey
Front Immunol. 2020; 11: 515556. Published online 2020 Oct 15. doi:Â 10.3389/fimmu.2020.515556
Bevacizumab use in the frontline, maintenance and recurrent settings for ovarian cancerCarolyn E Haunschild, Krishnansu S Tewari
Future Oncol. 2020 Mar; 16(7): 225â246. Published online 2019 Nov 20. doi:Â 10.2217/fon-2019-0042
PF-06439535 (a Bevacizumab Biosimilar) Compared with Reference Bevacizumab (Avastin®), Both Plus Paclitaxel and Carboplatin, as First-Line Treatment for Advanced Non-Squamous Non-Small-Cell Lung Cancer: A Randomized, Double-Blind StudyNiels Reinmuth, Maciej Bryl, Igor Bondarenko, Kostas Syrigos, Vladimir Vladimirov, Manuela Zereu, Angel H. Bair, Fiona Hilton, Katherine Liau, Kazuo Kasahara
BioDrugs. 2019; 33(5): 555â570. Published online 2019 Jul 23. doi:Â 10.1007/s40259-019-00363-4
Heparin potentiates Avastin-mediated inhibition of VEGF binding to fibronectin and rescues Avastin activity at acidic pHDivyabharathy Tsiros, Casey E. Sheehy, Surenna Pecchia, Matthew A. Nugent
J Biol Chem. 2019 Nov 15; 294(46): 17603â17611. Published online 2019 Oct 10. doi:Â 10.1074/jbc.RA119.009194
Glioblastoma endothelium drives bevacizumabâinduced infiltrative growth via modulation of PLXDC1Maria Laura Falchetti, Quintino Giorgio D'Alessandris, Simone Pacioni, Mariachiara Buccarelli, Liliana Morgante, Stefano Giannetti, Valentina Lulli, Maurizio Martini, Luigi Maria Larocca, Eliza Vakana, Louis Stancato, Lucia RicciâVitiani, Roberto Pallini
Int J Cancer. 2019 Mar 15; 144(6): 1331â1344. Published online 2018 Dec 16. doi:Â 10.1002/ijc.31983
Anti-Angiogenic Activity Of Bevacizumab-Bearing Dexamethasone-Loaded PLGA Nanoparticles For Potential Intravitreal ApplicationsJiaxin Liu, Xueyan Zhang, Ge Li, Fei Xu, Shuang Li, Lesheng Teng, Youxin Li, Fengying Sun
Int J Nanomedicine. 2019; 14: 8819â8834. Published online 2019 Nov 8. doi:Â 10.2147/IJN.S217038
A comparative pharmacokinetic study of DRL_BZ, a candidate biosimilar of bevacizumab, with Avastin® (EU and US) in healthy male subjectsChris Wynne, Christian Schwabe, Sonica Sachdeva Batra, Luis LopezâLazaro, Suresh Kankanwadi
Br J Clin Pharmacol. 2018 Oct; 84(10): 2352â2364. Published online 2018 Jul 26. doi:Â 10.1111/bcp.13691
Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degenerationLorenzo Moja, Ersilia Lucenteforte, Koren H Kwag, Vittorio Bertele, Annalisa Campomori, Usha Chakravarthy, Roberto DâAmico, Kay Dickersin, Laurent Kodjikian, Kristina Lindsley, Yoon Loke, Maureen Maguire, Daniel F Martin, Alessandro Mugelli, Bernd Mühlbauer, Isabel Püntmann, Barnaby Reeves, Chris Rogers, Christine Schmucker, Manju L Subramanian, Gianni Virgili
Cochrane Database Syst Rev. Author manuscript; available in PMC 2015 Sep 15.
Published in final edited form as: Cochrane Database Syst Rev. 2014; 9: CD011230. Published online 2014 Sep 15. doi:Â 10.1002/14651858.CD011230.pub2
Bevacizumab for glioblastoma: current indications, surgical implications, and future directionsBrandyn A. Castro, Manish K. Aghi
Neurosurg Focus. Author manuscript; available in PMC 2016 Apr 21.
Published in final edited form as: Neurosurg Focus. 2014 Dec; 37(6): E9.
Use of bevacizumab in recurrent glioblastomaAshley Ghiaseddin, Katherine B Peters
CNS Oncol. 2015 May; 4(3): 157â169. Published online 2015 Apr 23. doi:Â 10.2217/cns.15.8
A phase I, randomized, single-dose pharmacokinetic study comparing sb8 (bevacizumab biosimilar) with reference bevacizumab in healthy volunteersDonghoon Shin, Yoon Jung Lee, Jihye Choi, Dahyoung Lee, Minjeong Park, Magdalena Petkova
Cancer Chemother Pharmacol. 2020; 86(4): 567â575. Published online 2020 Sep 19. doi:Â 10.1007/s00280-020-04144-7
Aflibercept exhibits VEGF binding stoichiometry distinct from bevacizumab and does not support formation of immune-like complexesDouglas A. MacDonald, Joel Martin, Kathir K. Muthusamy, Jiann-Kae Luo, Erica Pyles, Ashique Rafique, Tammy Huang, Terra Potocky, Yang Liu, Jingtai Cao, Françoise Bono, Nathalie Delesque, Pierre Savi, John Francis, Ali Amirkhosravi, Todd Meyer, Carmelo Romano, Meredith Glinka, George D. Yancopoulos, Neil Stahl, Stanley J. Wiegand, Nicholas Papadopoulos
Angiogenesis. 2016; 19: 389â406. Published online 2016 May 27. doi:Â 10.1007/s10456-016-9515-8
A Quininib Analogue and Cysteinyl Leukotriene Receptor Antagonist Inhibits Vascular Endothelial Growth Factor (VEGF)-independent Angiogenesis and Exerts an Additive Antiangiogenic Response with BevacizumabClare T. Butler, Alison L. Reynolds, Miriam Tosetto, Eugene T. Dillon, Patrick J. Guiry, Gerard Cagney, Jacintha O'Sullivan, Breandán N. Kennedy
J Biol Chem. 2017 Mar 3; 292(9): 3552â3567. Published online 2016 Dec 29. doi:Â 10.1074/jbc.M116.747766
Mesoporous silica nanoparticles as a delivery system for improving antiangiogenic therapyJian-Guo Sun, Qin Jiang, Xiao-Pei Zhang, Kun Shan, Bai-Hui Liu, Chen Zhao, Biao Yan
Int J Nanomedicine. 2019; 14: 1489â1501. Published online 2019 Feb 25. doi:Â 10.2147/IJN.S195504
Antiâvascular endothelial growth factor for neovascular ageârelated macular degenerationSharon D Solomon, Kristina Lindsley, Satyanarayana S Vedula, Magdalena G Krzystolik, Barbara S Hawkins, Cochrane Eyes and Vision Group
Cochrane Database Syst Rev. 2019 Mar; 2019(3): CD005139. Published online 2019 Mar 4. doi:Â 10.1002/14651858.CD005139.pub4
Real-world evidence of safety profile of intravitreal bevacizumab (Avastin) in an Indian scenarioPrashant Jain, Jay Sheth, Giridhar Anantharaman, Mahesh Gopalakrishnan
Indian J Ophthalmol. 2017 Jul; 65(7): 596â602. doi:Â 10.4103/ijo.IJO_992_16
A pharmacokinetic binding model for bevacizumab and VEGF165 in colorectal cancer patientsEirini Panoilia, Emilie Schindler, Epaminontas Samantas, Gerasimos Aravantinos, Haralabos P. Kalofonos, Christos Christodoulou, George P. Patrinos, Lena E. Friberg, Gregory Sivolapenko
Cancer Chemother Pharmacol. 2015; 75(4): 791â803. Published online 2015 Feb 17. doi:Â 10.1007/s00280-015-2701-3
|